Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Accumulated Depreciation (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Accumulated Depreciation for 6 consecutive years, with $21.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation rose 15.32% to $21.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.6 million, a 15.32% increase, with the full-year FY2025 number at $21.6 million, up 15.32% from a year prior.
  • Accumulated Depreciation was $21.6 million for Q4 2025 at TScan Therapeutics, up from $18.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $21.6 million in Q4 2025 to a low of $5.1 million in Q4 2021.
  • A 5-year average of $14.0 million and a median of $14.6 million in 2023 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 189.63% in 2021, then grew 15.32% in 2025.
  • TScan Therapeutics' Accumulated Depreciation stood at $5.1 million in 2021, then surged by 101.06% to $10.2 million in 2022, then soared by 42.83% to $14.6 million in 2023, then increased by 28.14% to $18.7 million in 2024, then grew by 15.32% to $21.6 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Accumulated Depreciation are $21.6 million (Q4 2025), $18.7 million (Q4 2024), and $14.6 million (Q4 2023).